NVO - Ozempic Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits | Benzinga
The rise of weight loss drugs like Wegovy and Mounjaro by Novo Nordisk (NYSE:NVO) is leading to new product developments across various sectors.
What Happened: Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shifting consumer habits, CNBC reported on Friday.
DSM Firmenich is exploring nutritional supplements to complement the effects of these weight loss drugs. CEO Dimitri de Vreeze told CNBC that this move is a natural progression for the industry.
"If you go to weight loss and you're successful, you move to the health, nutrition, lifestyle counter, because you basically want to continue what you have. There we come into play," de Vreeze told.
Swiss food giant Nestle has announced a new frozen food range aimed at users of GLP-1 drugs. CEO Mark Schneider emphasized that while weight loss drugs change consumer behaviors, nutritional ...